抗高血压新药研究进展  

Progress in New Drugs for Hypertension

作　　者：刘晓飞[1] 

机构地区：[1]卫生部中日友好医院心内科,北京市100029

出　　处：《中国全科医学》2012年第26期2969-2973,共5页Chinese General Practice

摘　　要：高血压是心脑血管疾病、肾脏疾病和死亡的主要危险因素之一,其发生涉及肾素-血管紧张素-醛固酮系统(RAAS)紊乱、内皮系统功能改变和自主神经的问题,特别是交感神经系统。其中RAAS的阻滞是当前药物抗高血压治疗的最主要靶点,新的抗高血压治疗的靶点也更可能与RAAS相关。针对RAAS系统和内皮系统的更高选择性的新型药物正在临床试验中,包括选择性醛固酮受体阻滞剂、醛固酮合酶抑制剂、直接肾素阻滞剂和选择性内皮素A受体拮抗剂,这些药物已显示出较好的安全性、有效性和耐受性。本文综述这些药物治疗高血压的临床研究进展。Hypertension, one of the main risk factors of cardiovascular, cerebrovascular, renal diseases and death, results from disorders of renin - angiotensin - aldosterone system （ RAAS）, changes of endothelial function and problems of auto- nomic nervous system, especially those of sympathetic nervous system. Inhibition of RAAS is a main target of hypertensive drugs, and new targets are more likely to be related to RAAS. Anti - hypertensive drugs more selective to RAAS and endothelial system are in clinical tests, including aldosterone -receptor antagonists, aldosterone synthase inhibitor, direct renin inhibitors and en- dothelin- A receptor antagonis, which have revealed good safety, efficacy and tolerance. This review summarizes the clinical progress in new drugs for hypertension.

关 键 词：高血压 肾素-血管紧张素-醛固酮系统 药物疗法 新药 

分 类 号：R544.1[医药卫生—心血管疾病] R972.4[医药卫生—内科学]